Supplementation of polyunsaturated fatty acids, magnesium and zinc in children seeking medical advice for attention-deficit/hyperactivity problems - an observational cohort study

Background Polyunsaturated fatty acids are essential nutrients for humans. They are structural and functional components of cell membranes and pre-stages of the hormonally and immunologically active eicosanoids. Recent discoveries have shown that the long-chained omega-3 fatty acids eicosapentaenoic...

Full description

Saved in:
Bibliographic Details
Published inLipids in health and disease Vol. 9; no. 1; p. 105
Main Authors Huss, Michael, Völp, Andreas, Stauss-Grabo, Manuela
Format Journal Article
LanguageEnglish
Published London BioMed Central 24.09.2010
BioMed Central Ltd
BMC
Subjects
Online AccessGet full text
ISSN1476-511X
1476-511X
DOI10.1186/1476-511X-9-105

Cover

Abstract Background Polyunsaturated fatty acids are essential nutrients for humans. They are structural and functional components of cell membranes and pre-stages of the hormonally and immunologically active eicosanoids. Recent discoveries have shown that the long-chained omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) also play an important role in the central nervous system. They are essential for normal brain functioning including attention and other neuropsychological skills. Materials and methods In our large observational study we monitored 810 children from 5 to 12 years of age referred for medical help and recommended for consuming polyunsaturated fatty acids (PUFA) in combination with zinc and magnesium by a physician over a period of at least 3 months. The food supplement ESPRICO ® (further on referred to as the food supplement) is developed on the basis of current nutritional science and containing a combination of omega-3 and omega-6 fatty acids as well as magnesium and zinc. Study objective was to evaluate the nutritional effects of the PUFA-zinc-magnesium combination on symptoms of attention deficit, impulsivity, and hyperactivity as well as on emotional problems and sleep related parameters. Assessment was performed by internationally standardised evaluation scales, i.e. SNAP-IV and SDQ. Tolerance (adverse events) and acceptance (compliance) of the dietary therapy were documented. Results After 12 weeks of consumption of a combination of omega-3 and omega-6 fatty acids as well as magnesium and zinc most subjects showed a considerable reduction in symptoms of attention deficit and hyperactivity/impulsivity assessed by SNAP-IV. Further, the assessment by SDQ revealed fewer emotional problems at the end of the study period compared to baseline and also sleeping disorders. Mainly problems to fall asleep, decreased during the 12 week nutritional therapy. Regarding safety, no serious adverse events occurred. A total of 16 adverse events with a possible causal relationship to the study medication were reported by 14 children (1.7%) and only 5.2% of the children discontinued the study due to acceptance problems. Continuation of consumption of the food supplement was recommended by the paediatricians for 61.1% of the children. Conclusion Our results suggest a beneficial effect of a combination of omega-3 and omega-6 fatty acids as well as magnesium and zinc consumption on attentional, behavioural, and emotional problems of children and adolescents. Thus, considering the behavioural benefit in combination with the low risk due to a good safety profile, the dietary supplementation with PUFA in combination with zinc and magnesium can be recommended.
AbstractList Background Polyunsaturated fatty acids are essential nutrients for humans. They are structural and functional components of cell membranes and pre-stages of the hormonally and immunologically active eicosanoids. Recent discoveries have shown that the long-chained omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) also play an important role in the central nervous system. They are essential for normal brain functioning including attention and other neuropsychological skills. Materials and methods In our large observational study we monitored 810 children from 5 to 12 years of age referred for medical help and recommended for consuming polyunsaturated fatty acids (PUFA) in combination with zinc and magnesium by a physician over a period of at least 3 months. The food supplement ESPRICO.sup.[R] .sup.(further on referred to as the food supplement) is developed on the basis of current nutritional science and containing a combination of omega-3 and omega-6 fatty acids as well as magnesium and zinc. Study objective was to evaluate the nutritional effects of the PUFA-zinc-magnesium combination on symptoms of attention deficit, impulsivity, and hyperactivity as well as on emotional problems and sleep related parameters. Assessment was performed by internationally standardised evaluation scales, i.e. SNAP-IV and SDQ. Tolerance (adverse events) and acceptance (compliance) of the dietary therapy were documented. Results After 12 weeks of consumption of a combination of omega-3 and omega-6 fatty acids as well as magnesium and zinc most subjects showed a considerable reduction in symptoms of attention deficit and hyperactivity/impulsivity assessed by SNAP-IV. Further, the assessment by SDQ revealed fewer emotional problems at the end of the study period compared to baseline and also sleeping disorders. Mainly problems to fall asleep, decreased during the 12 week nutritional therapy. Regarding safety, no serious adverse events occurred. A total of 16 adverse events with a possible causal relationship to the study medication were reported by 14 children (1.7%) and only 5.2% of the children discontinued the study due to acceptance problems. Continuation of consumption of the food supplement was recommended by the paediatricians for 61.1% of the children. Conclusion Our results suggest a beneficial effect of a combination of omega-3 and omega-6 fatty acids as well as magnesium and zinc consumption on attentional, behavioural, and emotional problems of children and adolescents. Thus, considering the behavioural benefit in combination with the low risk due to a good safety profile, the dietary supplementation with PUFA in combination with zinc and magnesium can be recommended.
Abstract Background Polyunsaturated fatty acids are essential nutrients for humans. They are structural and functional components of cell membranes and pre-stages of the hormonally and immunologically active eicosanoids. Recent discoveries have shown that the long-chained omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) also play an important role in the central nervous system. They are essential for normal brain functioning including attention and other neuropsychological skills. Materials and methods In our large observational study we monitored 810 children from 5 to 12 years of age referred for medical help and recommended for consuming polyunsaturated fatty acids (PUFA) in combination with zinc and magnesium by a physician over a period of at least 3 months. The food supplement ESPRICO® (further on referred to as the food supplement) is developed on the basis of current nutritional science and containing a combination of omega-3 and omega-6 fatty acids as well as magnesium and zinc. Study objective was to evaluate the nutritional effects of the PUFA-zinc-magnesium combination on symptoms of attention deficit, impulsivity, and hyperactivity as well as on emotional problems and sleep related parameters. Assessment was performed by internationally standardised evaluation scales, i.e. SNAP-IV and SDQ. Tolerance (adverse events) and acceptance (compliance) of the dietary therapy were documented. Results After 12 weeks of consumption of a combination of omega-3 and omega-6 fatty acids as well as magnesium and zinc most subjects showed a considerable reduction in symptoms of attention deficit and hyperactivity/impulsivity assessed by SNAP-IV. Further, the assessment by SDQ revealed fewer emotional problems at the end of the study period compared to baseline and also sleeping disorders. Mainly problems to fall asleep, decreased during the 12 week nutritional therapy. Regarding safety, no serious adverse events occurred. A total of 16 adverse events with a possible causal relationship to the study medication were reported by 14 children (1.7%) and only 5.2% of the children discontinued the study due to acceptance problems. Continuation of consumption of the food supplement was recommended by the paediatricians for 61.1% of the children. Conclusion Our results suggest a beneficial effect of a combination of omega-3 and omega-6 fatty acids as well as magnesium and zinc consumption on attentional, behavioural, and emotional problems of children and adolescents. Thus, considering the behavioural benefit in combination with the low risk due to a good safety profile, the dietary supplementation with PUFA in combination with zinc and magnesium can be recommended.
Background Polyunsaturated fatty acids are essential nutrients for humans. They are structural and functional components of cell membranes and pre-stages of the hormonally and immunologically active eicosanoids. Recent discoveries have shown that the long-chained omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) also play an important role in the central nervous system. They are essential for normal brain functioning including attention and other neuropsychological skills. Materials and methods In our large observational study we monitored 810 children from 5 to 12 years of age referred for medical help and recommended for consuming polyunsaturated fatty acids (PUFA) in combination with zinc and magnesium by a physician over a period of at least 3 months. The food supplement ESPRICO ® (further on referred to as the food supplement) is developed on the basis of current nutritional science and containing a combination of omega-3 and omega-6 fatty acids as well as magnesium and zinc. Study objective was to evaluate the nutritional effects of the PUFA-zinc-magnesium combination on symptoms of attention deficit, impulsivity, and hyperactivity as well as on emotional problems and sleep related parameters. Assessment was performed by internationally standardised evaluation scales, i.e. SNAP-IV and SDQ. Tolerance (adverse events) and acceptance (compliance) of the dietary therapy were documented. Results After 12 weeks of consumption of a combination of omega-3 and omega-6 fatty acids as well as magnesium and zinc most subjects showed a considerable reduction in symptoms of attention deficit and hyperactivity/impulsivity assessed by SNAP-IV. Further, the assessment by SDQ revealed fewer emotional problems at the end of the study period compared to baseline and also sleeping disorders. Mainly problems to fall asleep, decreased during the 12 week nutritional therapy. Regarding safety, no serious adverse events occurred. A total of 16 adverse events with a possible causal relationship to the study medication were reported by 14 children (1.7%) and only 5.2% of the children discontinued the study due to acceptance problems. Continuation of consumption of the food supplement was recommended by the paediatricians for 61.1% of the children. Conclusion Our results suggest a beneficial effect of a combination of omega-3 and omega-6 fatty acids as well as magnesium and zinc consumption on attentional, behavioural, and emotional problems of children and adolescents. Thus, considering the behavioural benefit in combination with the low risk due to a good safety profile, the dietary supplementation with PUFA in combination with zinc and magnesium can be recommended.
Polyunsaturated fatty acids are essential nutrients for humans. They are structural and functional components of cell membranes and pre-stages of the hormonally and immunologically active eicosanoids. Recent discoveries have shown that the long-chained omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) also play an important role in the central nervous system. They are essential for normal brain functioning including attention and other neuropsychological skills. In our large observational study we monitored 810 children from 5 to 12 years of age referred for medical help and recommended for consuming polyunsaturated fatty acids (PUFA) in combination with zinc and magnesium by a physician over a period of at least 3 months. The food supplement ESPRICO.sup.[R] .sup.(further on referred to as the food supplement) is developed on the basis of current nutritional science and containing a combination of omega-3 and omega-6 fatty acids as well as magnesium and zinc. Study objective was to evaluate the nutritional effects of the PUFA-zinc-magnesium combination on symptoms of attention deficit, impulsivity, and hyperactivity as well as on emotional problems and sleep related parameters. Assessment was performed by internationally standardised evaluation scales, i.e. SNAP-IV and SDQ. Tolerance (adverse events) and acceptance (compliance) of the dietary therapy were documented. After 12 weeks of consumption of a combination of omega-3 and omega-6 fatty acids as well as magnesium and zinc most subjects showed a considerable reduction in symptoms of attention deficit and hyperactivity/impulsivity assessed by SNAP-IV. Further, the assessment by SDQ revealed fewer emotional problems at the end of the study period compared to baseline and also sleeping disorders. Mainly problems to fall asleep, decreased during the 12 week nutritional therapy. Regarding safety, no serious adverse events occurred. A total of 16 adverse events with a possible causal relationship to the study medication were reported by 14 children (1.7%) and only 5.2% of the children discontinued the study due to acceptance problems. Continuation of consumption of the food supplement was recommended by the paediatricians for 61.1% of the children. Our results suggest a beneficial effect of a combination of omega-3 and omega-6 fatty acids as well as magnesium and zinc consumption on attentional, behavioural, and emotional problems of children and adolescents. Thus, considering the behavioural benefit in combination with the low risk due to a good safety profile, the dietary supplementation with PUFA in combination with zinc and magnesium can be recommended.
Polyunsaturated fatty acids are essential nutrients for humans. They are structural and functional components of cell membranes and pre-stages of the hormonally and immunologically active eicosanoids. Recent discoveries have shown that the long-chained omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) also play an important role in the central nervous system. They are essential for normal brain functioning including attention and other neuropsychological skills.BACKGROUNDPolyunsaturated fatty acids are essential nutrients for humans. They are structural and functional components of cell membranes and pre-stages of the hormonally and immunologically active eicosanoids. Recent discoveries have shown that the long-chained omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) also play an important role in the central nervous system. They are essential for normal brain functioning including attention and other neuropsychological skills.In our large observational study we monitored 810 children from 5 to 12 years of age referred for medical help and recommended for consuming polyunsaturated fatty acids (PUFA) in combination with zinc and magnesium by a physician over a period of at least 3 months. The food supplement ESPRICO® (further on referred to as the food supplement) is developed on the basis of current nutritional science and containing a combination of omega-3 and omega-6 fatty acids as well as magnesium and zinc. Study objective was to evaluate the nutritional effects of the PUFA-zinc-magnesium combination on symptoms of attention deficit, impulsivity, and hyperactivity as well as on emotional problems and sleep related parameters. Assessment was performed by internationally standardised evaluation scales, i.e. SNAP-IV and SDQ. Tolerance (adverse events) and acceptance (compliance) of the dietary therapy were documented.MATERIALS AND METHODSIn our large observational study we monitored 810 children from 5 to 12 years of age referred for medical help and recommended for consuming polyunsaturated fatty acids (PUFA) in combination with zinc and magnesium by a physician over a period of at least 3 months. The food supplement ESPRICO® (further on referred to as the food supplement) is developed on the basis of current nutritional science and containing a combination of omega-3 and omega-6 fatty acids as well as magnesium and zinc. Study objective was to evaluate the nutritional effects of the PUFA-zinc-magnesium combination on symptoms of attention deficit, impulsivity, and hyperactivity as well as on emotional problems and sleep related parameters. Assessment was performed by internationally standardised evaluation scales, i.e. SNAP-IV and SDQ. Tolerance (adverse events) and acceptance (compliance) of the dietary therapy were documented.After 12 weeks of consumption of a combination of omega-3 and omega-6 fatty acids as well as magnesium and zinc most subjects showed a considerable reduction in symptoms of attention deficit and hyperactivity/impulsivity assessed by SNAP-IV. Further, the assessment by SDQ revealed fewer emotional problems at the end of the study period compared to baseline and also sleeping disorders. Mainly problems to fall asleep, decreased during the 12 week nutritional therapy. Regarding safety, no serious adverse events occurred. A total of 16 adverse events with a possible causal relationship to the study medication were reported by 14 children (1.7%) and only 5.2% of the children discontinued the study due to acceptance problems. Continuation of consumption of the food supplement was recommended by the paediatricians for 61.1% of the children.RESULTSAfter 12 weeks of consumption of a combination of omega-3 and omega-6 fatty acids as well as magnesium and zinc most subjects showed a considerable reduction in symptoms of attention deficit and hyperactivity/impulsivity assessed by SNAP-IV. Further, the assessment by SDQ revealed fewer emotional problems at the end of the study period compared to baseline and also sleeping disorders. Mainly problems to fall asleep, decreased during the 12 week nutritional therapy. Regarding safety, no serious adverse events occurred. A total of 16 adverse events with a possible causal relationship to the study medication were reported by 14 children (1.7%) and only 5.2% of the children discontinued the study due to acceptance problems. Continuation of consumption of the food supplement was recommended by the paediatricians for 61.1% of the children.Our results suggest a beneficial effect of a combination of omega-3 and omega-6 fatty acids as well as magnesium and zinc consumption on attentional, behavioural, and emotional problems of children and adolescents. Thus, considering the behavioural benefit in combination with the low risk due to a good safety profile, the dietary supplementation with PUFA in combination with zinc and magnesium can be recommended.CONCLUSIONOur results suggest a beneficial effect of a combination of omega-3 and omega-6 fatty acids as well as magnesium and zinc consumption on attentional, behavioural, and emotional problems of children and adolescents. Thus, considering the behavioural benefit in combination with the low risk due to a good safety profile, the dietary supplementation with PUFA in combination with zinc and magnesium can be recommended.
Polyunsaturated fatty acids are essential nutrients for humans. They are structural and functional components of cell membranes and pre-stages of the hormonally and immunologically active eicosanoids. Recent discoveries have shown that the long-chained omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) also play an important role in the central nervous system. They are essential for normal brain functioning including attention and other neuropsychological skills. In our large observational study we monitored 810 children from 5 to 12 years of age referred for medical help and recommended for consuming polyunsaturated fatty acids (PUFA) in combination with zinc and magnesium by a physician over a period of at least 3 months. The food supplement ESPRICO® (further on referred to as the food supplement) is developed on the basis of current nutritional science and containing a combination of omega-3 and omega-6 fatty acids as well as magnesium and zinc. Study objective was to evaluate the nutritional effects of the PUFA-zinc-magnesium combination on symptoms of attention deficit, impulsivity, and hyperactivity as well as on emotional problems and sleep related parameters. Assessment was performed by internationally standardised evaluation scales, i.e. SNAP-IV and SDQ. Tolerance (adverse events) and acceptance (compliance) of the dietary therapy were documented. After 12 weeks of consumption of a combination of omega-3 and omega-6 fatty acids as well as magnesium and zinc most subjects showed a considerable reduction in symptoms of attention deficit and hyperactivity/impulsivity assessed by SNAP-IV. Further, the assessment by SDQ revealed fewer emotional problems at the end of the study period compared to baseline and also sleeping disorders. Mainly problems to fall asleep, decreased during the 12 week nutritional therapy. Regarding safety, no serious adverse events occurred. A total of 16 adverse events with a possible causal relationship to the study medication were reported by 14 children (1.7%) and only 5.2% of the children discontinued the study due to acceptance problems. Continuation of consumption of the food supplement was recommended by the paediatricians for 61.1% of the children. Our results suggest a beneficial effect of a combination of omega-3 and omega-6 fatty acids as well as magnesium and zinc consumption on attentional, behavioural, and emotional problems of children and adolescents. Thus, considering the behavioural benefit in combination with the low risk due to a good safety profile, the dietary supplementation with PUFA in combination with zinc and magnesium can be recommended.
Audience Academic
Author Stauss-Grabo, Manuela
Huss, Michael
Völp, Andreas
AuthorAffiliation 2 Psy Consult Scientific Services, Fuchstanzstr. 107, 60489 Frankfurt/Main, Germany
3 Engelhard Arzneimittel GmbH & Co.KG, Herzbergstrasse 3, 61138 Niederdorfelden, Germany
1 Department for Child and Adolescent Psychiatry, Johannes Gutenberg-University, Mainz, Langenbeckstr. 1; 55131 Mainz, Germany
AuthorAffiliation_xml – name: 2 Psy Consult Scientific Services, Fuchstanzstr. 107, 60489 Frankfurt/Main, Germany
– name: 3 Engelhard Arzneimittel GmbH & Co.KG, Herzbergstrasse 3, 61138 Niederdorfelden, Germany
– name: 1 Department for Child and Adolescent Psychiatry, Johannes Gutenberg-University, Mainz, Langenbeckstr. 1; 55131 Mainz, Germany
Author_xml – sequence: 1
  givenname: Michael
  surname: Huss
  fullname: Huss, Michael
  email: michael.huss@ukmainz.de
  organization: Department for Child and Adolescent Psychiatry, Johannes Gutenberg-University, Mainz
– sequence: 2
  givenname: Andreas
  surname: Völp
  fullname: Völp, Andreas
  organization: Psy Consult Scientific Services
– sequence: 3
  givenname: Manuela
  surname: Stauss-Grabo
  fullname: Stauss-Grabo, Manuela
  organization: Engelhard Arzneimittel GmbH & Co.KG
BackLink https://www.ncbi.nlm.nih.gov/pubmed/20868469$$D View this record in MEDLINE/PubMed
BookMark eNp1kktv1DAUhSNURB-wZocsWLAhrZ3ETrxBqioelSqxACR2lh83Mx4SO9jOSMPP4hfimWlLW1Flkej6nO9e35zj4sB5B0XxkuBTQjp2RpqWlZSQHyUvCaZPiqPbysGd78PiOMYVxhVuGXtWHFa4Y13D-FHx5-s8TQOM4JJM1jvkezT5YTO7KNMcZAKDepnSBkltTXyHRrlwEO08IukM-m2dRtYhvbSDCeBQBPhp3QKNYKyWA5JmbTWg3geUKblL7lEa6K226Wy5mSBIneza5gZT8CpPElGZ0cirCGG9myljtF_6kFBMs9k8L572cojw4vp9Unz_-OHbxefy6suny4vzq1JTXqcS-ppWXSVrwxkjrdK85pISRTrCGNe90pR2mirVAVG1Aixbw5u2qzDtTaua-qS43HONlysxBTvKsBFeWrEr-LAQMiSrBxAcKtNy08iGqgZYzxXlrMJNSynJsC3r_Z41zSqvRudFBDncg94_cXYpFn4tKk4pq7sMeHsNCP7XDDGJ0UYNwyAd-DmKlnZd3XYdz8rXD5QrP4e8xCg4riqKGdvi3uxFC5nHt673uaveIsV5VfOGE95WWXX6H1V-DIxW5yT2NtfvGV7dvebt_W7ylgV0L9DBxxigFzkHu5-cyXYQBIttrsU2uWKbXMFzjWbf2QPfDfpxB947Yla6BYR_a3jM8hcFqAyq
CitedBy_id crossref_primary_10_1080_19390211_2018_1481165
crossref_primary_10_1016_j_clnesp_2024_05_011
crossref_primary_10_1007_s12402_013_0107_9
crossref_primary_10_1146_annurev_nutr_012809_104635
crossref_primary_10_1007_s12519_019_00227_5
crossref_primary_10_1186_s12887_021_02631_1
crossref_primary_10_1016_j_bbi_2019_05_016
crossref_primary_10_1016_j_eujim_2022_102183
crossref_primary_10_1007_s12011_022_03517_8
crossref_primary_10_2174_1871527321666220720103923
crossref_primary_10_1007_s11920_017_0762_1
crossref_primary_10_1007_s12011_024_04098_4
crossref_primary_10_1093_nutrit_nuaa103
crossref_primary_10_2174_1871527321666220517205813
crossref_primary_10_3390_nu16183113
crossref_primary_10_3390_biomedicines9080850
crossref_primary_10_1053_j_tcam_2018_08_006
crossref_primary_10_1016_j_clnesp_2018_03_126
crossref_primary_10_3390_molecules25194440
crossref_primary_10_12968_bjnn_2014_10_1_29
crossref_primary_10_4103_ijpvm_IJPVM_546_17
crossref_primary_10_1038_s41390_024_03729_9
crossref_primary_10_1007_s40675_017_0091_2
crossref_primary_10_1080_1028415X_2021_1963064
crossref_primary_10_1111_jsr_12135
crossref_primary_10_1016_j_ejmhg_2015_05_008
crossref_primary_10_3109_15622975_2011_600292
crossref_primary_10_3390_nu13114059
crossref_primary_10_1007_s12035_018_0899_x
crossref_primary_10_1016_j_pnpbp_2018_11_012
crossref_primary_10_1016_j_ejmhg_2016_04_009
crossref_primary_10_1192_bjp_bp_112_114942
crossref_primary_10_3390_nu10030344
crossref_primary_10_3390_nu14235111
crossref_primary_10_1007_s00394_021_02527_x
crossref_primary_10_3390_nu16223865
crossref_primary_10_1097_YCO_0b013e32834776bd
crossref_primary_10_1016_j_nut_2012_07_020
crossref_primary_10_1016_j_plefa_2015_10_004
crossref_primary_10_1089_act_2011_17403
crossref_primary_10_1038_s41598_023_49283_y
crossref_primary_10_3390_children1030261
crossref_primary_10_1016_j_ajp_2019_101868
crossref_primary_10_1016_j_smrv_2017_07_004
crossref_primary_10_1891_1559_4343_14_1_41
crossref_primary_10_1016_j_plefa_2014_01_004
ContentType Journal Article
Copyright Huss et al; licensee BioMed Central Ltd. 2010
COPYRIGHT 2010 BioMed Central Ltd.
2010 Huss et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright ©2010 Huss et al; licensee BioMed Central Ltd. 2010 Huss et al; licensee BioMed Central Ltd.
Copyright_xml – notice: Huss et al; licensee BioMed Central Ltd. 2010
– notice: COPYRIGHT 2010 BioMed Central Ltd.
– notice: 2010 Huss et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
– notice: Copyright ©2010 Huss et al; licensee BioMed Central Ltd. 2010 Huss et al; licensee BioMed Central Ltd.
DBID C6C
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7X7
7XB
88E
8FD
8FE
8FH
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
DWQXO
FR3
FYUFA
GHDGH
GNUQQ
HCIFZ
K9.
LK8
M0S
M1P
M7P
P64
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
RC3
7X8
5PM
DOA
DOI 10.1186/1476-511X-9-105
DatabaseName Springer Nature OA Free Journals
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Technology Research Database
ProQuest SciTech Collection
ProQuest Natural Science Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials Local Electronic Collection Information
Biological Science Collection
ProQuest Central
Natural Science Collection
ProQuest One Community College
ProQuest Central
Engineering Research Database
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
ProQuest Biological Science Collection
ProQuest Health & Medical Collection
Medical Database
Biological Science Database
Biotechnology and BioEngineering Abstracts
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
Genetics Abstracts
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest Central Student
Technology Research Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Natural Science Collection
ProQuest Central China
ProQuest Central
ProQuest One Applied & Life Sciences
ProQuest Health & Medical Research Collection
Genetics Abstracts
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Health & Medical Research Collection
Biological Science Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Biological Science Collection
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
ProQuest Hospital Collection (Alumni)
Biotechnology and BioEngineering Abstracts
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
Engineering Research Database
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList



Publicly Available Content Database
MEDLINE - Academic
MEDLINE
Database_xml – sequence: 1
  dbid: C6C
  name: Springer Nature OA Free Journals
  url: http://www.springeropen.com/
  sourceTypes: Publisher
– sequence: 2
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 3
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 4
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 5
  dbid: BENPR
  name: ProQuest Central
  url: http://www.proquest.com/pqcentral?accountid=15518
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Anatomy & Physiology
EISSN 1476-511X
EndPage 105
ExternalDocumentID oai_doaj_org_article_9e2d79d4a45b4e6f9b5962047551fd74
PMC2955638
2503569281
A239491972
20868469
10_1186_1476_511X_9_105
Genre Clinical Trial
Journal Article
GeographicLocations Germany
GeographicLocations_xml – name: Germany
GroupedDBID ---
0R~
29L
2VQ
2WC
4.4
53G
5GY
5VS
7X7
88E
8FE
8FH
8FI
8FJ
A8Z
AAFWJ
AAHBH
AAJSJ
AASML
ABDBF
ABUWG
ACGFO
ACGFS
ACPRK
ACUHS
ADBBV
ADRAZ
ADUKV
AENEX
AFKRA
AFPKN
AHBYD
AHMBA
AHSBF
AHYZX
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
BAPOH
BAWUL
BBNVY
BCNDV
BENPR
BFQNJ
BHPHI
BMC
BPHCQ
BVXVI
C6C
CCPQU
CS3
DIK
E3Z
EAD
EAP
EAS
EBD
EBLON
EBS
EJD
EMB
EMK
EMOBN
ESTFP
ESX
F5P
FYUFA
GROUPED_DOAJ
GX1
H13
HCIFZ
HH5
HMCUK
HYE
IAO
IGS
IHR
INH
INR
IPNFZ
ITC
KQ8
LK8
M1P
M48
M7P
M~E
O5R
O5S
OK1
OVT
P2P
P6G
PGMZT
PHGZM
PHGZT
PIMPY
PJZUB
PPXIY
PQGLB
PQQKQ
PROAC
PSQYO
PUEGO
RBZ
RIG
RNS
ROL
RPM
RSV
SBL
SOJ
SV3
TR2
TUS
U2A
UKHRP
W2D
WOQ
WOW
XSB
AAYXX
ALIPV
CITATION
-A0
3V.
ACRMQ
ADINQ
C24
CGR
CUY
CVF
ECM
EIF
FRP
NPM
PMFND
7XB
8FD
8FK
AZQEC
DWQXO
FR3
GNUQQ
K9.
P64
PKEHL
PQEST
PQUKI
PRINS
RC3
7X8
5PM
ID FETCH-LOGICAL-c593t-ef35282a3d96617bc939a51b181669cfbc558c5bb8e1b3be0a7d9478205fd7b43
IEDL.DBID 7X7
ISSN 1476-511X
IngestDate Wed Aug 27 01:27:59 EDT 2025
Thu Aug 21 18:13:01 EDT 2025
Sat Sep 27 18:00:35 EDT 2025
Fri Jul 25 19:28:23 EDT 2025
Tue Jun 17 21:19:31 EDT 2025
Tue Jun 10 20:42:11 EDT 2025
Wed Feb 19 02:10:38 EST 2025
Tue Jul 01 03:47:13 EDT 2025
Thu Apr 24 22:57:29 EDT 2025
Sat Sep 06 07:33:20 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Atomoxetine
Final Interview
Attention Deficit Hyperactivity Disorder
Attention Deficit Hyperactivity Disorder Symptom
Food Supplement
Language English
License This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c593t-ef35282a3d96617bc939a51b181669cfbc558c5bb8e1b3be0a7d9478205fd7b43
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Article-2
ObjectType-Feature-1
content type line 23
OpenAccessLink https://www.proquest.com/docview/902250668?pq-origsite=%requestingapplication%
PMID 20868469
PQID 902250668
PQPubID 42587
PageCount 1
ParticipantIDs doaj_primary_oai_doaj_org_article_9e2d79d4a45b4e6f9b5962047551fd74
pubmedcentral_primary_oai_pubmedcentral_nih_gov_2955638
proquest_miscellaneous_758837889
proquest_journals_902250668
gale_infotracmisc_A239491972
gale_infotracacademiconefile_A239491972
pubmed_primary_20868469
crossref_citationtrail_10_1186_1476_511X_9_105
crossref_primary_10_1186_1476_511X_9_105
springer_journals_10_1186_1476_511X_9_105
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2010-09-24
PublicationDateYYYYMMDD 2010-09-24
PublicationDate_xml – month: 09
  year: 2010
  text: 2010-09-24
  day: 24
PublicationDecade 2010
PublicationPlace London
PublicationPlace_xml – name: London
– name: England
PublicationTitle Lipids in health and disease
PublicationTitleAbbrev Lipids Health Dis
PublicationTitleAlternate Lipids Health Dis
PublicationYear 2010
Publisher BioMed Central
BioMed Central Ltd
BMC
Publisher_xml – name: BioMed Central
– name: BioMed Central Ltd
– name: BMC
SSID ssj0020766
Score 2.1611485
Snippet Background Polyunsaturated fatty acids are essential nutrients for humans. They are structural and functional components of cell membranes and pre-stages of...
Polyunsaturated fatty acids are essential nutrients for humans. They are structural and functional components of cell membranes and pre-stages of the...
Background Polyunsaturated fatty acids are essential nutrients for humans. They are structural and functional components of cell membranes and pre-stages of...
Abstract Background: Polyunsaturated fatty acids are essential nutrients for humans. They are structural and functional components of cell membranes and...
Abstract Background Polyunsaturated fatty acids are essential nutrients for humans. They are structural and functional components of cell membranes and...
SourceID doaj
pubmedcentral
proquest
gale
pubmed
crossref
springer
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 105
SubjectTerms Adolescent
Affective Symptoms
Attention
Attention Deficit Disorder with Hyperactivity - diet therapy
Attention Deficit Disorder with Hyperactivity - physiopathology
Attention Deficit Disorder with Hyperactivity - psychology
Attention Deficit Hyperactivity Disorder
Biomedical and Life Sciences
Child
Child, Preschool
Children
Children & youth
Clinical Nutrition
Cohort Studies
Diet therapy
Dietary Supplements - adverse effects
Fatty acids
Fatty Acids, Omega-3 - adverse effects
Fatty Acids, Omega-3 - therapeutic use
Fatty Acids, Omega-6 - adverse effects
Fatty Acids, Omega-6 - therapeutic use
Female
Food and nutrition
Health aspects
Humans
Hyperactivity
Hyperkinesis
Impulsive Behavior
Life Sciences
Lipidology
Magnesium - adverse effects
Magnesium - therapeutic use
Magnesium in the body
Male
Medical Biochemistry
Nutrition
Parents - psychology
Patient Compliance
Sleep Wake Disorders
Studies
Surveys and Questionnaires
Unsaturated fatty acids
Zinc - administration & dosage
Zinc - adverse effects
Zinc - therapeutic use
Zinc in the body
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQD4gLgpZHaEFzQDwkTDeJHcfHBVFVSOVEpb1ZduzQlbrZqskelp_FL2TGyYamqOLC1XYetsfjbzzjbxh7rRHD2jrUHKFxxkVWK-7yUvKAhaFQQaeRZ_vsW3F6Lr4u5OJGqi-KCevpgfuBO9Yh80p7YYV0IhS1dpQvZiYUbvW1V5EJdKZnO2NqMLXQOu_vFamCI6RYDKQ-aVkcj2Vcow6Sk_0o0vb_rZxv7E63IydvuU_jrnTyiD0c4CTM-248ZvdCs88O5g2a0qstvIEY4BlPzvfZ_bPBj37AfsVknn3gOM0MrGu4Wl9uN01LRJ-IPz3Utuu2YKulbz_Ayv5AnbjcrMA2Hn4umwqWDexugkMbAh25w6p3-4D1pIAAATEQf2eMqOQ-EFtFd3yBpm-8m0VpK2DIaNMCx1fD2o2nxPgayt573UGkwH3Czk--fP98yofsDbySOu94qIk4JrO5R4sqVa7SubYydSl5KnVVu0rKspLOlSF1uQszq7wWRN8ncV6dyJ-yvWbdhOcM0jQIr3IvSmLrc4UrvSVso53ChSBmCfu4m0NTDdTmlGHj0kQTpywMTbqhSTcay2TC3o0PXPWsHnc3_URCMTYjOu5YgEJqBiE1_xLShL0lkTKkNPDHKjvcfcDuEf2WmVOCek0Z4BJ2NGmJi72aVB_uhNIMyqY1GnGYROhYJgzGWnqQ4ueasN60Bq3CmDlAJ-xZL8FjhzI0ahGEYo2ayPakx9OaZnkRicgzTfRy-Nn3u1Xw56fuGM4X_2M4D9mDPoiDnINHbK-73oSXiA079yqqgd9-wGGI
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Scholars Portal Journals: Open Access
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELagSIgLghZoaEFzQDwk0m4SO4kPCC2IqkIqJ1bam2XHTrvSblI2WYnlZ_ELmXGyKVtarn4kcTxjz3jG38fYK4k2rC5dGaJpHIc8LrPQJLkIHRa6NHMy8jjbZ9_S0wn_OhXTKzqg_gc2N7p2xCc1Wc6Pfv5Yf0SF_-AVPk-PI56lIRoO01DiqiLusns-WER5fHwIKcTosKc9ts8Nnba2JY_e_-8a_dcmdT2B8loU1W9OJ4_Yw96qhHEnBo_ZHVftsr1xhR71Yg2vwed5-gP0XXb_rA-n77HfntOzyx-nCYK6hMt6vl5VDeF9ohlqodRtuwZdzGzzHhb6HJfG2WoBurLwa1YVMKtgcyEcGufo5B0WXfQHtKV1CNAuBoLx9ImVoXUEWtEeX6AH7K9oEXsF9MQ2DYT4aKjNcFiMjyES32ULHgn3CZucfPn--TTsSRzCQsikDV1J-DGxTiw6VlFmCplILSITUcBSFqUphMgLYUzuIpMYN9KZlZxQ_ERpM8OTp2ynqiu3zyCKHLdZYnlOoH0mNbnVZOJIk6E-8FHAjjZzqIoe4ZyINubKezp5qmjSFU26klgmAvZ26HDZgXvc3vQTCcXQjFC5fUG9PFe9kivpYptJyzUXhru0lIa4jUY8Q7MUB8MD9oZESpE044cVur8CgcMjFC41Jp56SURwATvcaok6X2xVH2yEUm1URkk0xwRakHnAYKiljpRGV7l61Sh0Dj2BgAzYs06ChwHF6NuiLYo12ZZsb414u6aaXXg88lgSyhy-9t1GC64-6pbf-fy_AzhgD7okDQr-HbKddrlyL9D2a81Lr9N_ANp3WcM
  priority: 102
  providerName: Scholars Portal
– databaseName: Springer Nature OA Free Journals
  dbid: C6C
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwELagSIgLghZo2oLmgHhImG4SO4mPy4qqQionKu3NsmOHrtTNVk32sPys_kJmnGxoCj1w9SOJ4_H4G8_4G8beKsSwpvIVR2iccJFUObdpIbnHQp_lXsWBZ_vse3Z6Lr7N5bwnSaK7MLf993GRHccizziCgjlXqDHkQ_ZIotYlUZ5ls8GyQmM863l7_tFptOUEZv6_9e-tDehucOQdD2nYeE6esac9YoRpN8XP2QNf77K9aY3W8nID7yDEcIbD8V32-Kx3le-xm5Cvs4sNp58PqwquVpebdd0QlydCTAeVadsNmHLhmk-wND9R7S3WSzC1g1-LuoRFDdvL3tB4T6fqsOw8O2Ac6RhAzAtE0RmCJrnzREjRHl-gdRuuX1FmCuiT1jTA8dGwssNBMD6GEvRetxBYbl-w85OvP2anvE_QwEup0pb7irhhEpM6NJri3JYqVUbGNiZnpCorW0pZlNLawsc2tX5icqcEMfTJyuVWpC_ZTr2q_T6DOPbC5akTBRHy2cwWzhB8UTZHWReTiH3ezqEue_ZySqJxqYMVU2SaJl3TpGuFZTJiH4YOVx1xx_1Nv5BQDM2IcTsUoCDqfgFr5ROXKyeMkFb4rFKW8hZNRI6QEwcjIvaeREqTXsAPK01_vQGHRwxbeko56BUleYvY0aglrudyVH24FUrd65NGK4RaEtFhETEYaqkjhcjVfrVuNBp-ITmAitirToKHASVotyLOxJp8JNujEY9r6sVF4BpPFDHI4Ws_blfBn4-653ce_EfbQ_akC8cgN98R22mv1_41orzWvgkr_De1IU72
  priority: 102
  providerName: Springer Nature
Title Supplementation of polyunsaturated fatty acids, magnesium and zinc in children seeking medical advice for attention-deficit/hyperactivity problems - an observational cohort study
URI https://link.springer.com/article/10.1186/1476-511X-9-105
https://www.ncbi.nlm.nih.gov/pubmed/20868469
https://www.proquest.com/docview/902250668
https://www.proquest.com/docview/758837889
https://pubmed.ncbi.nlm.nih.gov/PMC2955638
https://doaj.org/article/9e2d79d4a45b4e6f9b5962047551fd74
Volume 9
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3db9MwELdgkxAvCDY-wkblB8SHRGiTOHH8hLpq01SpEwIm9c2KY2ertCalSR_Kn8VfyJ3jZmRovKSS7Xy49p3vfOffj5C3AmzYrDCFD6Zx6LOw4L6K0tg3UGgSbkRgcbZnF8n5JZvO47nLzaldWuVOJ1pFrasc98iHAhabGNbH9Mvqp4-kURhcdQwaD8l-AIYIMjfw-a2_BS564tB8gjQZBownPtgXc1-A8ol7C5HF6_9XK_-1LN1NmbwTN7XL0dlT8sTZkXTcDvwz8sCUB-RwXIIPvdzSd9Rmdtot8wPyaOYC6Ifkt2XxbDPGcUhoVdBVdbPdlDUifILhqWmRNc2WZvlC15_oMrsCZbjYLGlWavprUeZ0UdLdEXBaG4N77XTZxntoplHzULCEKQJ32lRKXxuEqWiG1-Dz2kNZyFdBHZVNTX14NK1Utz0Mj0Ha3nVDLfbtc3J5dvpjcu472gY_j0XU-KZAxJgwizS4UgFXuYhEFgcqwBClyAuVx3Gax0qlJlCRMqOMa8EQty8uNFcsekH2yqo0rwgNAsM0jzRLEaZPJSrVGRo1QnGQADbyyOfdGMrcYZojtcaNtL5NmkgcdImDLgWUxR750N2wauE87m96gpOia4Y43LagWl9JJ9ZSmFBzoVnGYsVMUgiFbEYjxsEQhc4wj7zHKSVRW8CH5Zk79ADdQ9wtOUZmeoHUbx457rUEKc971Ue7SSmdlqllJxMeoV0t3oiJc6WpNrUEd9BSBgiPvGxncNehELxZsD6hhvfmdq_H_ZpycW0RyEOBuHLw2o87Kbj9qHv-ztf_7cARedymZWC475jsNeuNeQPWXqMGVqYHZH88nn6fwu_J6cXXb1A6SSYDu4MC1xlL4XoZjv8AQPJd0A
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLZGJwEvCDYuZQP8wFUitEmcix8m1MGmjq0TQpvUN2PHzlZpTUqTCpWfxTv_jXOcC3RovO01dty4Pj4Xn-PvI-Q5Bx9WpiZ1wDX2HOalkaP8OHAMPDRhZLhrcbZHx-HwlH0aB-M18qu5C4NllY1OtIpa5wmekfc4GJsA7GP8fvbNQdIoTK42DBqyZlbQOxZhrL7XcWiW3yGCK3YOPsJyv_C8_b2TD0OnJhlwkoD7pWNSxDfxpK_B8XcjlXCfy8BVLibUeJKqJAjiJFAqNq7ylenLSHOGKHNBqiPFfBj3BllneH7SIeu7e8efv7QRXz8KwxpPyI3Dnsui0AEPZ-xwUH_Biim0jAH_2oW_DOPlos1LmVtrEPfvkju1J0sHlejdI2sm2yCbgwyi-OmSvqS2ttQe2m-Qm6M6hb9Jfloe0apmHYWC5imd5RfLRVYgxii4vpqmsiyXVCYTXbylU3kG6niymFKZafpjkiV0ktHmEjotjMHTfjqtMk5UatR9FHxxitChtpjT0QaBMsreOUTd9loYMmbQmkynoA4MTXPVHlDDMEgcPC-pRd-9T06vZU0fkE6WZ-YRoa5rmI58zWIEClShirVEt4qrCPYg63fJu2YNRVKjqiO5x4Ww0VUcClx0gYsuODwLuuR1-8KsAhS5uusuCkXbDZHA7YN8fiZqxSK48XTENZMsUMyEKVfIp9RnEWwEmAzrklcoUgL1FXxYIutrFzA9RP4SA8_njCP5XJdsr_QEPZOsNG81QilqPVeIdld2CW1b8UUs3ctMvigEBKSWtIB3ycNKgtsJeRBPg_8LLdGKbK_MeLUlm5xbDHSPI7Id_OybZhf8-agr_s7H_53AM3JreDI6EkcHx4db5HZVJILJx23SKecL8wR8z1I9rXc4JV-vW6n8Bgrjmns
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwELagSBUXBC2P0AI-IB4SYTeJncTH5bEqj1YcWGlvlh07baRustpkD8vP4hcy4zwghR64-pHEsWf8jWf8DSHPBWBYldvcB2gc-izME19HKfctFNo4sSJwPNunZ_HJgn1e8mUXm1P30e69S7K904AsTWUzWZu8FfE0ngQsiX2ACktfgB7hN8ktBhs1RnQtwtlgb4GJHndsPv_oNNqIHF__31r5j23pasjkFb-p247md8mdDkfSWTvx98gNWx6Qw1kJNvRqR19QF9npjswPyP5p50A_JD9dFs82YhynhFY5XVeXu21ZI8MnAE9Dc9U0O6qywtRv6EqdgzIstiuqSkN_FGVGi5L2V8BpbS2etdNV6--hyqDmoYCEKRJ3ulBK31ikqWgmF2DzuktZmK-CdqlsaurDo2mlh-NheAym7d001HHf3ieL-cfv70_8Lm2Dn3ERNb7NkTEmVJEBUypIdCYioXigA3RRiizXGedpxrVObaAjbacqMYIhbx_PTaJZ9IDslVVpHxEaBJaZJDIsRZo-HevUKAQ1QicgAWzqkbf9HMqs4zTH1BqX0tk2aSxx0iVOuhRQxj3yauiwbuk8rm_6DhfF0Ax5uF1BtTmXnVhLYUOTCMMU45rZOBcasxlNWQJAFAbDPPISl5REbQEflqnu0gMMD3m35Awz0wtM_eaR41FLkPJsVH3UL0rZaZlaCgBgHDBj6hE61GJHDJwrbbWtJZiDLmWA8MjDdgUPAwrBmgX0CTXJaG2PRjyuKYsLx0AeCuSVg9e-7qXg90dd8zsf_0fbZ2T_24e5_Prp7MsRud3Ga6Af8JjsNZutfQIwsNFPnbD_Ar5RWks
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Supplementation+of+polyunsaturated+fatty+acids%2C+magnesium+and+zinc+in+children+seeking+medical+advice+for+attention-deficit%2Fhyperactivity+problems+-+an+observational+cohort+study&rft.jtitle=Lipids+in+health+and+disease&rft.au=Huss%2C+Michael&rft.au=V%C3%B6lp%2C+Andreas&rft.au=Stauss-Grabo%2C+Manuela&rft.date=2010-09-24&rft.pub=BioMed+Central&rft.eissn=1476-511X&rft.volume=9&rft.spage=105&rft_id=info:doi/10.1186%2F1476-511X-9-105&rft.externalDocID=2503569281
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1476-511X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1476-511X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1476-511X&client=summon